1. Home
  2. IIF vs RCEL Comparison

IIF vs RCEL Comparison

Compare IIF & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Morgan Stanley India Investment Fund Inc.

IIF

Morgan Stanley India Investment Fund Inc.

HOLD

Current Price

$21.58

Market Cap

204.7M

Sector

Finance

ML Signal

HOLD

Logo Avita Medical Inc.

RCEL

Avita Medical Inc.

HOLD

Current Price

$4.58

Market Cap

171.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IIF
RCEL
Founded
1993
N/A
Country
United States
United States
Employees
N/A
226
Industry
Trusts Except Educational Religious and Charitable
Medical/Dental Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
204.7M
171.5M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
IIF
RCEL
Price
$21.58
$4.58
Analyst Decision
Buy
Analyst Count
0
5
Target Price
N/A
$7.88
AVG Volume (30 Days)
37.3K
227.7K
Earning Date
01-01-0001
05-14-2026
Dividend Yield
13.94%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$17.17
Revenue Next Year
N/A
$49.82
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$19.83
$3.22
52 Week High
$28.37
$7.12

Technical Indicators

Market Signals
Indicator
IIF
RCEL
Relative Strength Index (RSI) 47.95 54.92
Support Level $19.83 $4.02
Resistance Level $22.66 $5.80
Average True Range (ATR) 0.36 0.39
MACD -0.05 0.02
Stochastic Oscillator 37.42 40.42

Price Performance

Historical Comparison
IIF
RCEL

About IIF Morgan Stanley India Investment Fund Inc.

Morgan Stanley India Investment Fund, Inc. is the United States based non-diversified, closed-end management investment company. Its investment objective is to achieve long-term capital appreciation through investment in equity securities of Indian Issuers. The company's portfolio of investments consists of the investment in different sectors such as auto components, banks, capital markets, construction and engineering, pharmaceuticals and others.

About RCEL Avita Medical Inc.

Avita is largely a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently used in most of the 140 US burn centers. Despite having product approval in Australia, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region, although international sales, particularly in Japan, are growing. Avita is domiciled, and has its primary listing, in the US.

Share on Social Networks: